PNC-27 (30 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency: one subcutaneous injection daily, taken at a consistent time and rotated across abdomen, thighs, and upper arms to limit local irritation. At 10 mg/mL every dose in this protocol is a very small draw, from 1 unit at 100 mcg to 5 units at 500 mcg, so a 30 or 50 unit insulin syringe reads the graduations more accurately than a 100 unit barrel and no dose here comes close to needing a split injection. The critical caveat sits on top of all of it: no authoritative human dosing exists for PNC-27, the FDA warns that its safety has not been established, and any amount above a few hundred micrograms per day is purely speculative.

Results Timeline

Sequence described in the research record. Individual response varies.

• Weeks 1 to 2: 100 mcg daily, which is 1 unit at 10 mg/mL, the opening step of the titration.
• Weeks 3 to 4: 200 mcg daily, or 2 units, the first increase.
• Weeks 5 to 8: 300 mcg daily, or 3 units, and week 8 is the short end of the described course.
• Weeks 9 to 12: 400 mcg daily, or 4 units, completing the standard 12 week course.
• Weeks 13 to 16: 500 mcg daily, or 5 units, only where the course is extended. No human data describes what happens at any point on this curve.

Reconstitution Steps

1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label with date and concentration; refrigerate at 2 to 8 °C, protected from light. At 10 mg/mL, 1 unit = 0.01 mL » 100 mcg on a U-100 insulin syringe.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at minus 20 °C or colder, with minus 80 °C ideal; short term refrigeration at 2 to 8 °C is acceptable.
• Reconstituted: refrigerate at 2 to 8 °C, use within approximately 30 days, and avoid freeze-thaw cycles.

• Allow vials to reach room temperature before opening to reduce condensation.
• Inspect before each use: the solution should be clear and colorless, and is discarded if discolored or if particles are visible.

Supplies Needed

The figures below are based on the 8 to 16 week daily protocol with gradual titration, which works out to 0.7 mg in each of the first two weeks and rises to 3.5 mg per week at the top step of 500 mcg daily.

Peptide Vials (PNC-27, 30 mg vial):

• The full titration totals about 12.6 mg over 8 weeks, about 23.8 mg over 12 weeks, and about 37.8 mg over 16 weeks, so one 30 mg vial covers an 8 or 12 week course and two vials cover a 16 week course.

Insulin Syringes (U-100):

• Per week: 7 insulin syringes, one per day, ideally 30 or 50 unit barrels since every dose here is 5 units or less.
• Full cycle: 56 syringes over 8 weeks, 84 over 12 weeks, and 112 over 16 weeks.

Bacteriostatic Water (10 mL bottles):

• Each 30 mg vial takes 3.0 mL, so one 10 mL bottle of bacteriostatic water covers 3 vials, which means a single bottle is sufficient for anything from 8 to 16 weeks.

Alcohol Swabs:

• Per injection: 2 swabs, one for the vial stopper and one for the site, which is 14 per week.
• Full cycle: 112 swabs over 8 weeks, 168 over 12 weeks, and 224 over 16 weeks, the last of which is 3 boxes of 100.

Important Notes

Practical considerations for consistency and safety.

• The daily dose is far smaller than the vial. At 100 to 500 mcg per day a reconstituted 30 mg vial holds far more peptide than can be used inside the roughly 30 day window for refrigerated reconstituted material, so most of a vial expires unused unless it is reconstituted in smaller portions.
• Use a new sterile insulin syringe for every injection and dispose of it in a sharps container.
• Rotate injection sites to reduce local irritation, and inject slowly, waiting a few seconds before withdrawing the needle.
• Document the daily dose and site rotation to maintain consistency, since the titration steps are easy to lose track of over a 16 week course.
• Every number on this page is an extrapolation. The preclinical work behind PNC-27 used intraperitoneal administration in mouse tumor models, not subcutaneous injection in people, so the route, the schedule, and the dose range are all inferred rather than tested.
• Regulatory Note: PNC-27 has no FDA approval, has never been tested in a human clinical trial, and has no established human safety or efficacy data. The FDA issued a safety communication in 2015 stating that PNC-27 products are unapproved and that their safety has not been established. It is sold and handled for research purposes only and is not for human consumption. The master sheet lists no WADA status for this compound.

How This Works

PNC-27 is a chimeric peptide built from a segment of the p53 tumor suppressor protein, residues 12 to 26, fused to a membrane penetrating leader sequence. Preclinical studies indicate that the p53 segment binds HDM-2 expressed on the surface of cancer cells, and that the leader sequence then drives the peptide into the membrane, destabilizing it and producing necrotic cell death rather than apoptosis, while normal cells that do not display surface HDM-2 are reportedly spared. Research in mouse tumor models has demonstrated inhibition of cancer cell growth using intraperitoneal administration. No human clinical studies have been conducted at any dose or by any route, so every dosing protocol in circulation, including the one on this page, remains a theoretical extrapolation from that preclinical work.

Benefits & Side Effects

Observations from the published record.

• Preclinical studies suggest selective cytotoxicity toward cancer cells that express abnormal p53/HDM-2 complexes, with normal cells spared.
• The proposed mechanism is direct membrane lysis rather than apoptosis in the affected cells, which is what distinguishes PNC-27 from conventional p53 pathway approaches.
• Tumor growth inhibition has been reported in mouse models, using intraperitoneal administration rather than the subcutaneous route this protocol describes.
• No human clinical data exists. There are no trials, no published human pharmacokinetics, and no human dose response information, so nothing on the benefit side has been demonstrated in people.
• No human safety data exists either. The FDA has explicitly warned that the safety and efficacy of PNC-27 have not been established, which means the side effect profile in people is simply unknown rather than known to be mild.
• The one effect that can be anticipated from the route is local: injection site reactions such as redness and irritation may occur with subcutaneous administration.

Lifestyle Factors

Complementary strategies for best outcomes.

• A balanced, nutrient-dense diet supports overall metabolic function during any research protocol of this length.
• Adequate sleep and active stress management support immune function and recovery.
• Qualified healthcare professionals are consulted before any experimental peptide use, which matters more here than usual because PNC-27 carries an explicit FDA warning and no human safety record.
• Careful injection site care and hygiene belong in the daily routine, since subcutaneous administration can produce redness and irritation and systematic site rotation limits those local reactions.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. PNC-27 induces tumor cell membrane lysis (Cancer Chemotherapy and Pharmacology, 2010).
2. FDA Drug Safety Communication: PNC-27 is unapproved; safety not established (2015).